EQS-News: Defence Therapeutics Inc. / Key word(s): MiscellaneousDEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH 10.01.2024 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC  .
Defence Therapeutics Inc.: Defence's AccuTOX(R) Impairs Lung Cancer Growth finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Defence Therapeutics Inc. , one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA has cleared today Study May Proceed.